DMT

Szabo et al., “The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells” (2016)

Katchborian-Neto et al., “Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson’s disease” (2020)

Argento et al., “Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada” (2019)

Palhano-Fontes et al., “Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression”, PsychoMed (2019)

Timmermann et al., “Neural correlates of the DMT experience assessed with multivariate EEG” (2019)

Pasquini et al., “Subacute effects of the psychedelic ayahuasca on the salience and default mode networks” (2020)

Pallavicini et al., “Neural and subjective effects of inhaled DMT in natural settings” (2020)

MDMA

MAPS, “MAPS – MDMA Investigator’s Brochure (10th Edition)” (2018)

Mithoefer et al., “MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials” (2019)

Rudnick & Wall, “The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release” (1992)

Carhart-Harris et al., “The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity” (2015)

Mitchell et al., “MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study” (2021)

Ibogaine

Knuijver et al., “Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study” (2022)

Schenberg et al., “Treating drug dependence with the aid of ibogaine: A qualitative study” (2017)

Mash et al., “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes” (2018)

Brown & Alper, “Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes” (2017)

Glue et al., “Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients” (2016)

Cappendijk & Dzoljic, “Inhibitory effects of ibogaine on cocaine self-administration in rats” (1993)

Dzoljic et al., “Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats” (1988)

Rezvani et al., “Attenuation of alcohol intake by Ibogaine in three strains of alcohol-preferring rats” (1995)

Maillet et al., “Noribogaine is a G-protein biased κ-opioid receptor agonist” (2015)

Psilocybin

Watts et al., “Patients’ Accounts of Increased ‘Connectedness’ and ‘Acceptance’ After Psilocybin for Treatment-Resistant Depression” (2017)

Griffiths et al, “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer” (2016)

Carhart-Harris, et al., “Trial of Psilocybin versus Escitalopram for Depression.”, N Engl J Med (2021)

Schindler et al., “Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin” (2020)

Hasler et al., “Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose effect study” (2004)

Sewell et al., “Response of cluster headache to psilocybin and LSD” (2006)

Moreno et al., “Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder” (2006)

Cognitive Impairment Associated with Schizophrenia

Charlson et al., “Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study” (2016)

Reichenberg et al., “Neuropsychological Function and Dysfunction in Schizophrenia and Psychotic Affective Disorders” (2009)

Laursen, Nordentoft & Mortensen, “Excess early mortality in schizophrenia” (2014)

Cloutier et al., “The Economic Burden of Schizophrenia in the United States in 2013” (2016)

Depression

Abbott, “COVID’s mental-health toll: how scientists are tracking a surge in depression”, Nature (2021)

Tew et al., “Impact of prior treatment exposure on response to antidepressant treatment in late life” Am J Geriatr Psychiatry (2006)

Spriggs et al., “Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder” (2020)

Pandarakalam, “Challenges of Treatment-resistant Depression” (2018)

Sussman et al., “Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System” (2019)

Gaynes et al., “Defining treatment‐resistant depression” (2019)

Anxiety

DeVane et al., “Anxiety Disorders in the 21st Century: Status, Challenges, Opportunities, and Comorbidity With Depression”, AJMC (2005)

DeMartini et al., “Generalized Anxiety Disorder” (2019)

Substance Use Disorder

Wilson et al., “Drug and opioid-involved overdose deaths – United States, 2017-2018” (2020)

Murphy, “The cost of opioid use disorder and the value of aversion” (2020)

Sinha, “New Findings on Biological Factors Predicting Addiction Relapse Vulnerability” (2011)

General

Patel et al., “The Lancet Commission on global mental health and sustainable development”, The Lancet (2018)

Salzer, “National Estimates of Recovery-Remission From Serious Mental Illness”, Psychiatry Online (2018)

Flanagan & Nichols, “Psychedelics as anti-inflammatory agents” (2018)

Vann Jones & O’Kelly, “Psychedelics as a Treatment for Alzheimer’s Disease Dementia” (2020)

Thompson et al., “Psychedelics as a novel approach to treating autoimmune conditions” (2020)

Szabo A., “Psychedelics and immunomodulation: novel approaches and therapeutic opportunities” (2015)

Lea et al., “Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders” (2020)

Inserra et al., “Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms”, Pharmacol Rev (2021)

Vollenweider & Preller, “Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders” (2020)

 

 

 

 

 

 

 

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit